rs4987188
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Structural debilitation of mutation G322D associated with MSH2 and their role in triple negative breast cancer.
|
30806579 |
2020 |
rs2363956
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
rs11540652
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Transcriptome profiling identified ADORA2B as up-regulated in basal-like TNBC cell lines with R248Q-mutated TP53, with shRNA-screening suggesting the potential for a synthetic-lethal interaction between these genes.
|
30349649 |
2018 |
rs861539
|
|
|
0.020 |
GeneticVariation |
BEFREE |
XRCC3 rs861539 TT is a potential predictive marker for TNBC in Taiwanese women and investigations in other populations are warranted for further universal application in cancer detection and prediction.
|
26543082 |
2016 |
rs11540652
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This study supports using the biological markers of high expression of mtp53 R273H or R248Q as additional diagnostics for TNBC resistant subtypes often found in the AA community.
|
26703669 |
2015 |
rs4987188
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The Gly322Asp polymorphism of the hMSH2 gene may be linked with TNBC occurrence in Polish women.
|
25134804 |
2015 |
rs861539
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, XRCC2 Arg188His and XRCC3 Thr241Met polymorphisms may be regarded as predictive factors of triple-negative breast cancer in female population.
|
24728564 |
2015 |
rs8170
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P = 3.31 × 10(-13)].
|
22331459 |
2012 |
rs8170
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
rs2363956
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The five SNPs were also associated with triple-negative breast cancer in a separate study of 2,301 triple-negative cases and 3,949 controls (P(trend) = 1 × 10⁻⁷) to P(trend) = 8 × 10⁻⁵; rs2363956 per-allele OR = 0.80, 95% CI 0.74-0.87, P(trend) = 1.1 × 10⁻⁷
|
20852631 |
2010 |
rs1042522
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, genetic variants in <i>TP53</i> were found in all TNBC tumors, with rs1042522 being the most frequent (94% of TNBC biopsies), which had not been previously reported in TNBC.
|
30867801 |
2019 |
rs13000023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
rs141366047
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
rs148047459
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
rs2491231
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs2491231 variant in the <i>FLT3</i> gene was identified in 84% (16/19) of the samples, which not yet reported for TNBC, to the best of our knowledge.
|
30867801 |
2019 |
rs2814778
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Frequency of the Duffy-null allele (rs2814778; an African ancestral variant adopted under selective pressure as protection against malaria) was associated with TNBC-specific risk (P < 0.0001), quantified West African Ancestry (P < 0.0001) and was more common in AA, Ghanaians, and TNBC cases.
|
31356281 |
2019 |
rs40239
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
rs4938723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Prognostic significance of miR-34 rs4938723 T > C polymorphism in triple negative breast cancer patients.
|
30935968 |
2019 |
rs56391007
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
rs769772228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα<sup>+</sup> T47D cells expressing mtp53 L194F.
|
30642351 |
2019 |
rs11615
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings firstly show that the T allele of ERCC1 rs11615 can serve as a predictive biomarker for breast cancer and TNBC.
|
30096175 |
2018 |
rs12075
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggested that rs12075 could be served as a key predictive factor of recurrence risk in breast cancer, especially for TNBC subtype.
|
30358125 |
2018 |
rs121913016
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
rs1235679626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these findings provide the first functional evidence for the M276I mutation in promoting TNBC progression.
|
30093560 |
2018 |